Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

D. P. Chew

doi:10.1055/s-0037-1619549

Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

D. P. Chew

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.

Original language	English
Pages (from-to)	142-148
Number of pages	7
Journal	Hamostaseologie
Volume	22
Issue number	3
DOIs	https://doi.org/10.1055/s-0037-1619549
Publication status	Published - 2002
Externally published	Yes

Keywords

Anticoagulant
Bivalirudin
Percutaneous coronary intervention
Thrombia inhibitor
Unstable angina

Access to Document

10.1055/s-0037-1619549Licence: In Copyright

Cite this

@article{ebc03d1b3d9f498e9837a7e64de5476b,

title = "Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures",

abstract = "Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.",

keywords = "Anticoagulant, Bivalirudin, Percutaneous coronary intervention, Thrombia inhibitor, Unstable angina",

author = "Chew, {D. P.}",

year = "2002",

doi = "10.1055/s-0037-1619549",

language = "English",

volume = "22",

pages = "142--148",

journal = "Hamostaseologie",

issn = "0720-9355",

publisher = "Springer ",

number = "3",

}

TY - JOUR

T1 - Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

AU - Chew, D. P.

PY - 2002

Y1 - 2002

N2 - Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.

AB - Among the antithrombotic therapies evaluated to date, the synthetic peptide bivalirudin is unique in its ability to reduce both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is a small peptide consisting of 20 amino acid residues that binds thrombin in a direct, reversible, and bivalent fashion. The agent is approved for use in the United States and New Zealand as an anticoagulant in patients with unstable angina undergoing PCI and may also prove beneficial in patients with acute coronary syndromes (ACS), acute myocardial infarction (AMI) and in patients undergoing coronary artery bypass graft (CABG) procedures. This article examines bivalirudin in more detail.

KW - Anticoagulant

KW - Bivalirudin

KW - Percutaneous coronary intervention

KW - Thrombia inhibitor

KW - Unstable angina

UR - http://www.scopus.com/inward/record.url?scp=0036375302&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1619549

DO - 10.1055/s-0037-1619549

M3 - Article

C2 - 12215763

VL - 22

SP - 142

EP - 148

JO - Hamostaseologie

JF - Hamostaseologie

SN - 0720-9355

IS - 3

ER -

Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this